GlassScriptPhysician profile
Rajesh A Persaud
NPI 1023384179
$5,948.92
in general payments reported to CMS, 2019-2025
44 companies · $956 in 2025
The $956 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2021: $706 · 2022: $939 · 2023: $1,024 · 2024: $1,473 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,439.11 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,323.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $474.20 | 2021-2025 | |
| Evoke Pharma, INC. | $468.89 | 2022-2024 | Gimoti |
| Lilly USA, LLC | $421.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $321.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $303.07 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Idorsia Pharmaceuticals US INC | $236.36 | 2022-2024 | Quviviq |
| Pfizer INC. | $235.07 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $201.42 | 2019-2023 | Dificid |
| Amgen INC. | $165.28 | 2023-2025 | Repatha, Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $136.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $129.72 | 2023-2025 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $124.86 | 2019 | |
| Daiichi Sankyo INC. | $115.42 | 2022-2025 | Injectafer |
| Glaxosmithkline, LLC. | $114.02 | 2021-2025 | Trelegy Ellipta, Arexvy |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $113.19 | 2022-2024 | Freestyle Libre 3 |
| Shield Therapeutics INC | $103.32 | 2024 | |
| Insmed, INC. | $100.81 | 2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.88 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $71.94 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $58.66 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $58.33 | 2019 | |
| Radius Health, INC. | $54.39 | 2024 | Tymlos |
| Sumitomo Pharma America, INC. | $44.63 | 2025 | Gemtesa |
| Corcept Therapeutics | $43.84 | 2023 | Korlym |
| Renalytix Ai, INC. | $42.74 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi-Aventis U.S. LLC | $35.58 | 2022 | |
| Insulet Corporation | $35.01 | 2024 | Omnipod |
| Astellas Pharma US INC | $33.81 | 2024-2025 | Veozah |
| Bausch Health US, LLC | $32.36 | 2024 | Wellbutrin, Aplenzin |
| Esperion Therapeutics, INC. | $32.29 | 2021-2023 | Nexletol |
| Biogen, INC. | $26.84 | 2025 | Skyclarys |
| Irhythm Technologies, INC. | $24.29 | 2023 | Zio Xt Patch |
| Chiesi USA, INC. | $21.58 | 2025 | Juxtapid |
| Philips North America LLC | $19.94 | 2024 | (Ck7) Extended Holter |
| E.R. Squibb & Sons, L.L.C. | $18.43 | 2021 | |
| Abbvie INC. | $16.78 | 2022 | |
| Lundbeck LLC | $15.91 | 2024 | Rexulti |
| Medtronic, INC. | $15.10 | 2024 | Closurefast |
| Abiomed | $14.45 | 2024 | |
| Hikma Pharmaceuticals USA | $13.52 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.52 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.49 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Persaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.